Summary

The pharmaceutical market is probably one of the most highly regulated fields in the world. The combination of a dynamic market, high demands and both private and public stakeholders has given rise to market access as an important commercial discipline:

Market access is about understanding the roles played by stakeholders and how to interact with them in order to get pharmaceuticals on the Danish market. It’s about the path from regulatory approval to usage by HCPs to treat patients with new medicines.

In this course, you enter the engine room of pharmaceutical product prioritisation in Denmark, and you learn what processes pharmaceutical products go through to gain access to the Danish market. You will be introduced to important stakeholders in the Danish healthcare system, including The Danish Medicines Council, the Danish Medicines Agency, Amgros and the regions, and you will get an introduction to the health economic analyses used in prioritisation decisions. In addition, through case work you will learn what innovative price agreements can and cannot do.

At the course, experienced market access professionals will benefit from updated knowledge about a dynamic market. Newcomers to the field of the market access and pharma consultants will gain a quick, broad introduction to the area and learn how key players in Danish pharmaceutical product prioritisation system think and act.

OTHER COURSE PARTICIPANTS SAY:

"The course provided both in-depth and practical focus on decision-making in institutions, e.g., in Danish HTAs and challenges with a new paradigm in approval of medicines, all the way down to individuals in these institutions – the course made a real difference in understanding their world."

Jakob Schmidt, Trade Commissioner - Life Science, Embassy of Canada

Keywords

• The Danish healthcare system
• Market access in Denmark
• Health Technology Assessment